A detailed history of Ares Financial Consulting, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Ares Financial Consulting, LLC holds 26 shares of ALKS stock, worth $755. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26
Holding current value
$755
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 29, 2026

BUY
$29.04 - $33.81 $755 - $879
26 New
26 $727,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.77B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Ares Financial Consulting, LLC Portfolio

Follow Ares Financial Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ares Financial Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ares Financial Consulting, LLC with notifications on news.